Sharing of Revenues From Sublicensees Sample Clauses

Sharing of Revenues From Sublicensees. If MMD grants a sublicense hereunder to any Third Party to make, have made, use, distribute for sale or sell GA-EPO covered by the TKT Patent Rights or which uses the TKT Technology in any country in the MMD Territory, MMD shall share with TKT, *************** *****, all up front monetary consideration received by MMD from such Third Party in connection therewith which are not based upon Net Sales or Net Revenues, as applicable, of GA-EPO sold by such Third Party sublicensee in such country.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Sharing of Revenues From Sublicensees. If TKT grants one or more sublicenses to research, develop, make, have made, distribute, sell or have sold GA-EPO to any Third Parties, at such point as TKT has received an aggregate of $[**] in up-front and milestone payments under such sublicenses, TKT shall pay to Aventis [**] percent ([**]%) of any incremental up-front and/or milestone payments in excess of $[**] received by TKT from such sublicensees. Notwithstanding anything else in this Section 7.2.3, Aventis shall have no right to receive any payment from TKT as a result of (i) TKT selling securities, including common stock of TKT, to a third party in connection with a sublicense or (ii) any sublicense to (A) research, develop, make or have made GA-EPO for distribution and sale in Japan, or (B) distribute, sell or have sold GA-EPO in Japan.
Sample 1

Related to Sharing of Revenues From Sublicensees

  • Royalties on Net Sales Novo will pay to Neose royalties as a percentage of annual Net Sales of each New Product during the Term at the applicable rates set forth in this Section 4.1 and in accordance with this Section 4:

  • Sublicense Income Company shall pay Medical School {***} of all Sublicense Income. Such amounts shall be due and payable within sixty (60) days after Company receives the relevant payment from the Sublicensee.

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

  • Net Sales The term “

  • Royalty Reductions (i) If a Licensed Product is generating Net Sales in a country or administrative region during the Royalty Term in such country at a time when there is no TESARO Patent that contains a Valid Claim Covering the composition of matter of such Licensed Product in such country or administrative region, then the royalty rate for such Licensed Product in such country or administrative region shall be reduced by [***].

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Sales Milestone Payments Licensee shall notify MTI of any Calendar Year in which annual Net Sales of a Licensed Product in such Calendar Year in all countries in the Territory reach the following thresholds for the first time within [***] days after the end of such Calendar Year, and shall make the following sales milestone payments to MTI within [***] days after receiving an invoice from MTI therefor: Annual Net Sales Threshold Sales Milestone Payment [***] [***] [***] [***] [***] [***] Each sales milestone payment is separate and may only be earned once for each Licensed Product, irrespective of the number of times such thresholds are achieved for such Licensed Product, but if more than one Net Sales threshold is reached in the same Calendar Year, all corresponding sales milestone payments shall be payable during such Calendar Year. For example, if annual Net Sales of a Licensed Product first reach [***] dollars [***] in Calendar Year 1, [***] dollars [***] shall be payable to MTI for such Calendar Year 1, however, if annual Net Sales of a Licensed Product first reach [***] dollars ($500,000,000) in Calendar Year 2 [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. (without first reaching [***] dollars [***] in Calendar Year 1), then both the [***] dollars [***] and the [***] dollars [***] sales milestone payments would be payable to MTI for such Calendar Year 2. Net Sales of the Co-Exploited Product in the United States, which are subject to profit and loss sharing pursuant to the Co-Exploitation Terms, shall be excluded from the annual Net Sales of such Co-Exploited Product for purposes of this Section 7.10.

  • Earned Royalty In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

Time is Money Join Law Insider Premium to draft better contracts faster.